PharmaPoint:精神分裂症 - 美國的醫藥品的預測與市場分析
Schizophrenia - US Drug Forecast and Market Analysis to 2025
|出版日期||內容資訊||英文 350 Pages
|PharmaPoint:精神分裂症 - 美國的醫藥品的預測與市場分析 Schizophrenia - US Drug Forecast and Market Analysis to 2025|
|出版日期: 2016年11月01日||內容資訊: 英文 350 Pages||
Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions). A multitude of antipsychotic products are currently available for the pharmacological management of schizophrenia, many of which are already available as inexpensive generics. Further patent and exclusivity losses in key franchises throughout the forecast period will act as a barrier to growth in the 7MM, making the schizophrenia market more competitive and crowded. Growth in the schizophrenia market is expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards significant unmet needs.
GlobalData estimates that drug sales for schizophrenia in the US reached $4.9 billion during 2015, making the US the largest market within the 7MM in this space. Sales are expected to initially decline to 2020 due to patent expiries of a number of brands during the forecast period, such as Otsuka's Abilify and Abilify Maintena; Vanda Pharmaceuticals' Fanapt; Janssen's Invega Sustenna, Invega Trinza, and Risperdal; Dainippon Sumitomo's Latuda; AstraZeneca's Seroquel XR; and Eli Lilly's Zyprexa Relprevv.